Jacob et al. demonstrated that brain organoids derived from pluripotent stem cells faithfully recapitulate both the genetic heterogeneity and the complex histoarchitecture of GBM as driver gene expression (e.g., EGFR mutations), offering a robust platform for the development of targeted and personalized therapies. The gene discussed is EGFR; the disease is glioblastoma.